Red blood cell alloimmunization mitigation strategies

Transfusion Medicine Reviews

Volumn 28, Issue 3, 2014, Pages 137-144

  Hendrickson, Jeanne E ^a   Tormey, Christopher A ^a,b   Shaz, Beth H ^c,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c NEW YORK BLOOD CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY;

ALLOIMMUNITY; ALLOIMMUNIZATION; ANTIBODY SCREENING; BLOOD TRANSFUSION; ERYTHROCYTE; ERYTHROCYTE PRESERVATION; GENOTYPE; HAZARD; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; LEUKAPHERESIS; NONHUMAN; PHENOTYPE; RECIPIENT; REVIEW; SPLENECTOMY; ANEMIA, HEMOLYTIC; ANIMAL; BLOOD GROUP INCOMPATIBILITY; CHEMISTRY; CYTOLOGY; ERYTHROCYTE TRANSFUSION; IMMUNOLOGY;

ANEMIA, HEMOLYTIC; ANIMALS; BLOOD GROUP INCOMPATIBILITY; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; GENOTYPE; HUMANS; ISOANTIBODIES; PHENOTYPE; SPLENECTOMY;

EID: 84903489893     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2014.04.008     Document Type: Review

References (89)

1. Whitaker B, Hinkins S. The 2011 National Blood Collection and Utilization Survey Report. In: Department of Health and Human Services, editor.2013.
2. Food and Drug Administration Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2013. FDA 2014, FDA.
3. Hillyer C.D., Shaz B.H., Winkler A.M., Reid M. Integrating molecular technologies for RBC typing and compatibility testing into blood centers and transfusion services. Transfus Med Rev 2008, 22:117-132.
4. Denomme G.A. Prospects for the provision of genotyped blood for transfusion. Br J Haematol 2013, 163:3-9.
5. Josephson C.D., Su L.L., Hillyer K.L., Hillyer C.D. Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfus Med Rev 2007, 21:118-133.
6. Aygun B., Padmanabhan S., Paley C., Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002, 42:37-43.
7. Vichinsky E.P., Earles A., Johnson R.A., Hoag M.S., Williams A., Lubin B. Alloimmunization in sickle-cell-anemia and transfusion of racially unmatched blood. N Engl J Med 1990, 322:1617-1621.
8. Higgins J.M., Sloan S.R. Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders. Blood 2008, 112:2546-2553.
9. Tatari-Calderone Z., Tamouza R., Le Bouder G.P., Dewan R., Luban N.L., Lasserre J., et al. The association of CD81 polymorphisms with alloimmunization in sickle cell disease. Clin Dev Immunol 2013, 2013:937846.
10. Chu C.C., Ho H.T., Lee H.L., Chan Y.S., Chang F.J., Wang C.L., et al. Anti-"Mi(a)" immunization is associated with HLA-DRB1*0901. Transfusion 2009, 49:472-478.
11. Chiaroni J., Dettori I., Ferrera V., Legrand D., Touinssi M., Mercier P., et al. HLA-DRB1 polymorphism is associated with Kell immunisation. Br J Haematol 2006, 132:374-378.
12. Picard C., Frassati C., Basire A., Buhler S., Galicher V., Ferrera V., et al. Positive association of DRB1 04 and DRB1 15 alleles with Fya immunization in a Southern European population. Transfusion 2009, 49:2412-2417.
13. Reviron D., Dettori I., Ferrera V., Legrand D., Touinssi M., Mercier P., et al. HLA-DRB1 alleles and Jk(a) immunization. Transfusion 2005, 45:956-959.
14. Hendrickson J.E., Roback J.D., Hillyer C.D., Easley K.A., Zimring J.C. Discrete Toll-like receptor agonists have differential effects on alloimmunization to transfused red blood cells. Transfusion 2008, 48:1869-1877.
15. Hendrickson J.E., Desmarets M., Deshpande S.S., Chadwick T.E., Hillyer C.D., Roback J.D., et al. Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion 2006, 46:1526-1536.
16. Stowell S.R., Girard-Pierce K.R., Smith N.H., Henry K.L., Arthur C.M., Zimring J.C., et al. Transfusion of murine red blood cells expressing the human KEL glycoprotein induces clinically significant alloantibodies. Transfusion 2014, 54:179-189.
17. Smith N.H., Hod E.A., Spitalnik S.L., Zimring J.C., Hendrickson J.E. Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. Blood 2012, 119:1566-1569.
18. Yazer M.H., Triulzi D.J., Shaz B., Kraus T., Zimring J.C. Does a febrile reaction to platelets predispose recipients to red blood cell alloimmunization?. Transfusion 2009, 49:1070-1075.
19. Papay P., Hackner K., Vogelsang H., Novacek G., Primas C., Reinisch W., et al. High risk of transfusion-induced alloimmunization of patients with inflammatory bowel disease. Am J Med 2012, 125:717.e1-717.e8.
20. Bao W., Zhong H., Li X., Lee M.T., Schwartz J., Sheth S., et al. Immune regulation in chronically transfused allo-antibody responder and nonresponder patients with sickle cell disease and beta-thalassemia major. Am J Hematol 2011, 86:1001-1006.
21. Yu J., Heck S., Yazdanbakhsh K. Prevention of red cell alloimmunization by CD25 regulatory T cells in mouse models. Am J Hematol 2007, 82:691-696.
22. Booth G.S., Miles M.R., Du L., Koyama T., Meier E.R., Luban N.L.C. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Blood 2013, 122:40.
23. JPAC-Joint United Kingdom Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee Transfusion handbook. Basics of blood groups and antibodies [Accessed: May 8, 2014]. http://www.transfusionguidelines.org.uk/transfusion-handbook/2-basics-of-blood-groups-and-antibodies.
24. Shirey R.S., Boyd J.S., Parwani A.V., Tanz W.S., Ness P.M., King K.E. Prophylactic antigen-matched donor blood for patients with warm autoantibodies: an algorithm for transfusion management. Transfusion 2002, 42:1435-1441.
25. Afenyi-Annan A., Bandarenko N. Transfusion practices for patients with sickle cell disease at a major academic center. Immunohematology 2006, 22:103-107.
26. Tahhan H.R., Holbrook C.T., Braddy L.R., Brewer L.D., Christie J.D. Antigen-matched donor blood in the transfusion management of patients with sickle-cell disease. Transfusion 1994, 34:562-569.
27. Lasalle-Williams M., Nuss R., Le T., Cole L., Hassell K., Murphy J.R., et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion 2011, 51:1732-1739.
28. Singer S.T., Wu V., Mignacca R., Kuypers F.A., Morel P., Vichinsky E.P. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood 2000, 96:3369-3373. [see comment].
29. Chou S.T., Jackson T., Vege S., Smith-Whitley K., Friedman D.F., Westhoff C.M. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013, 122:1062-1071.
30. Castilho L., Rios M., Bianco C., Pellegerino J., Alberto F.L., Saad S.T.O., et al. DNA-based typing of blood groups for the management of multiply-transfused sickle cell disease patients. Transfusion 2002, 42:232-238.
31. da Costa D.C., Pellegrino J., Guelsin G.A., Ribeiro K.A., Gilli S.C., Castilho L. Molecular matching of red blood cells is superior to serological matching in sickle cell disease patients. Rev Bras Hematol Hemoter 2013, 35:35-38.
32. Bakanay S.M., Ozturk A., Ileri T., Ince E., Yavasoglu S., Akar N., et al. Blood group genotyping in multi-transfused patients. Transfus Apher Sci 2013, 48:257-261.
33. O'Suoji C., Liem R.I., Mack A.K., Kingsberry P., Ramsey G., Thompson A.A. Alloimmunization in sickle cell anemia in the era of extended red cell typing. Pediatr Blood Cancer 2013, 60:1487-1491.
34. Rowley D.A. The formation of circulating antibody in the splenectomized human being following intravenous injection of heterologous erythrocytes. J Immunol 1950, 65:515-521.
35. Rozing J., Brons N.H., Bennner R. Effects of splenectomy on the humoral immune system. A study in neonatally and adult splenectomized mice. Immunology 1978, 34:909-917.
36. Hendrickson J.E., Stowell S.R., Smith N.H., Girard-Pierce K.R., Hudson K.E., Zimring J.C. Transfused RBCs can be immunogenic in splenectomized mice: of inflammation, adjuvants, and anamnestic responses. Transfusion 2012, 52:P1-030A. [Supplement].
37. Benner R., van Oudenaren A. Antibody formation in mouse bone marrow. IV. The influence of splenectomy on the bone marrow plaque-forming cell response to sheep red blood cells. Cell Immunol 1975, 19:167-182.
38. Thompson A.A., Cunningham M.J., Singer S.T., Neufeld E.J., Vichinsky E., Yamashita R., et al. Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. Br J Haematol 2011, 153:121-128.
39. Azarkeivan A., Ansari S., Ahmadi M.H., Hajibeigy B., Maghsudlu M., Nasizadeh S., et al. Blood transfusion and alloimmunization in patients with thalassemia: multicenter study. Pediatr Hematol Oncol 2011, 28:479-485.
40. Pahuja S., Pujani M., Gupta S.K., Chandra J., Jain M. Alloimmunization and red cell autoimmunization in multitransfused thalassemics of Indian origin. Hematology 2010, 15:174-177.
41. Gupta R., Singh D.K., Singh B., Rusia U. Alloimmunization to red cells in thalassemics: emerging problem and future strategies. Transfus Apher Sci 2011, 45:167-170.
42. Ho H.K., Ha S.Y., Lam C.K., Chan G.C., Lee T.L., Chiang A.K., et al. Alloimmunization in Hong Kong southern Chinese transfusion-dependent thalassemia patients. Blood 2001, 97:3999-4000.
43. McPherson M.E., Anderson A.R., Castillejo M.I., Hillyer C.D., Bray R.A., Gebel H.M., et al. HLA alloimmunization is associated with RBC antibodies in multiply transfused patients with sickle cell disease. Pediatr Blood Cancer 2010, 54:552-558.
44. Casanueva M., Valdes M.D., Ribera M.C. Lack of alloimmunization to D antigen in D-negative immunosuppressed liver transplant recipients. Transfusion 1994, 34:570-572.
45. Ramsey G., Hahn L.F., Cornell F.W., Boczkowski D.J., Staschak S., Clark R., et al. Low rate of Rhesus immunization from Rh-incompatible blood transfusions during liver and heart transplant surgery. Transplantation 1989, 47:993-995.
46. Hendrickson J., Saakadze N., Cadwell C.M., Upton J.W., Mocarski E.S., Hillyer C.D., et al. The spleen plays a central role in primary humoral alloimmunization to transfused mHEL red blood cells. Transfusion 2009, 49:1678-1684.
47. Girard-Pierce K., Stowell S.R., Smith N.H., Henry K.L., Zimring J.C., Hendrickson J.E. Marginal zone B cells mediate alloantibody formation to a clinically significant human RBC antigen in a murine model. Blood 2012, 120:843.
48. Gilson C.R., Patel S.R., Zimring J.C. CTLA4-Ig prevents alloantibody production and BMT rejection in response to platelet transfusions in mice. Transfusion 2012, 52:2209-2219.
49. Stephen J., Cairns L.S., Pickford W.J., Vickers M.A., Urbaniak S.J., Barker R.N. Identification, immunomodulatory activity, and immunogenicity of the major helper T-cell epitope on the K blood group antigen. Blood 2012, 119:5563-5574.
50. Judd W.J., Walter W.J., Steiner E.A. Clinical and laboratory findings on two patients with naturally occurring anti-Kell agglutinins. Transfusion 1981, 21:184-188.
51. Hudson K.E., Lin E., Hendrickson J.E., Lukacher A.E., Zimring J.C. Regulation of primary alloantibody response through antecedent exposure to a microbial T-cell epitope. Blood 2010, 115:3989-3996.
52. Strauss R.G., Cordle D.G., Quijana J., Goeken N.E. Comparing alloimmunization in preterm infants after transfusion of fresh unmodified versus stored leukocyte-reduced red blood cells. J Pediatr Hematol Oncol 1999, 21:224-230.
53. Patel S.R., Hendrickson J.E., Smith N.H., Cadwell C.M., Ozato K., Morse H.C., et al. Alloimmunization against RBC or PLT antigens is independent of TRIM21 expression in a murine model. Mol Immunol 2011, 48:909-913.
54. Vichinsky E., Neumayr L., Trimble S., Giardina P.J., Cohen A.R., Coates T., et al. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention. Transfusion 2014, 54:972-981.
55. Spanos T., Karageorga M., Ladis V., Peristeri J., Hatziliami A., Kattamis C. Red cell alloantibodies in patients with thalassemia. Vox Sang 1990, 58:50-55.
56. Rosse W.F., Gallagher D., Kinney T.R., Castro O., Dosik H., Moohr J., et al. Transfusion and alloimmunization in sickle-cell disease. Blood 1990, 76:1431-1437.
57. Blumberg N., Heal J.M., Gettings K.F. WBC reduction of RBC transfusions is associated with a decreased incidence of RBC alloimmunization. Transfusion 2003, 43:945-952.
58. van de Watering L., Hermans J., Witvliet M., Versteegh M., Brand A. HLA and RBC immunization after filtered and buffy coat-depleted blood transfusion in cardiac surgery: a randomized controlled trial. Transfusion 2003, 43:765-771.
59. Schonewille H., Brand A. Alloimmunization to red blood cell antigens after universal leucodepletion. A regional multicentre retrospective study. Br J Haematol 2005, 129:151-156.
60. Hendrickson J., Hod E.A., Spitalnik S.L., Hillyer C.D., Zimring J.C. Leukoreduction decreases alloimmunogenicity of transfused murine HOD RBCs. ASH Annual Meeting Abstracts 2009, 114:640.
61. D'Alessandro A., Liumbruno G., Grazzini G., Zolla L. Red blood cell storage: the story so far. Blood Transfus 2010, 8:82-88.
62. Hendrickson J.E., Hod E.A., Cadwell C.M., Eisenbarth S.C., Spiegel D.A., Tormey C.A., et al. Rapid clearance of transfused murine red blood cells is associated with recipient cytokine storm and enhanced alloimmunogenicity. Transfusion 2011, 51:2445-2454.
63. Hendrickson J.E., Hod E.A., Spitalnik S.L., Hillyer C.D., Zimring J.C. Storage of murine red blood cells enhances alloantibody responses to an erythroid-specific model antigen. Transfusion 2010, 50:642-648.
64. Hendrickson J.E., Hod E.A., Hudson K.E., Spitalnik S.L., Zimring J.C. Transfusion of fresh murine red blood cells reverses adverse effects of older stored red blood cells. Transfusion 2011, 51:2695-2702.
65. Stowell S.R., Smith N.H., Zimring J.C., Fu X., Palmer A.F., Fontes J., et al. Addition of ascorbic acid solution to stored murine red blood cells increases posttransfusion recovery and decreases microparticles and alloimmunization. Transfusion 2013, 53:2248-2257.
66. Yazer M.H., Triulzi D.J. Receipt of older RBCs does not predispose D-negative recipients to anti-D alloimmunization. Am J Clin Pathol 2010, 134:443-447.
67. Zalpuri S., Schonewille H., Middelburg R., van de Watering L., de Vooght K., Zimring J., et al. Effect of storage of red blood cells on alloimmunization. Transfusion 2013, 53:2795-2800.
68. Redman M., Regan F., Contreras M. A prospective study of the incidence of red cell allo-immunisation following transfusion. Vox Sang 1996, 71:216-220.
69. Tormey C.A., Fisk J., Stack G. Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion 2008, 48:2069-2076.
70. US Food and Drug Administration. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2009. In: US Department of Health and Human Services, editor. Rockville 2010.
71. Harm S.K., Yazer M.H., Monis G.F., Triulzi D.J., Aubuchon J.P., Delaney M. A centralized recipient database enhances the serologic safety of RBC transfusions for patients with sickle cell disease. Am J Clin Pathol 2014, 141:256-261.
72. Reverberi R. The persistence of red cell alloantibodies. Blood Transfus 2008, 6:225-234.
73. Tormey C.A., Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009, 49:505-512.
74. Unni N., Peddinghaus M., Tormey C.A., Stack G. Record fragmentation due to transfusion at multiple health care facilities: a risk factor for delayed hemolytic transfusion reactions. Transfusion 2014, 54:98-103.
75. Schwickerath V., Kowalski M., Menitove J.E. Regional registry of patient alloantibodies: first-year experience. Transfusion 2010, 50:1465-1470.
76. Delaney M., Dinwiddie S., Nester T.N., Aubuchon J.A. The immunohematologic and patient safety benefits of a centralized transfusion database. Transfusion 2013, 53:771-776.
77. Worel N., Greinix H.T., Supper V., Leitner G., Mitterbauer M., Rabitsch W., et al. Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning. Transfusion 2007, 47:1494-1502.
78. Tormey C.A., Stack G. Limiting the extent of a delayed hemolytic transfusion reaction with automated red blood cell exchange. Arch Pathol Lab Med 2013, 137:861-864.
79. Kalyanaraman M., Heidemann S.M., Sarnaik A.P., Meert K.L., Sarnaik S.A. Anti-s antibody-associated delayed hemolytic transfusion reaction in patients with sickle cell anemia. J Pediatr Hematol Oncol 1999, 21:70-73.
80. von Zabern I., Ehlers M., Grunwald U., Mauermann K., Greinacher A. Release of mediators of systemic inflammatory response syndrome in the course of a severe delayed hemolytic transfusion reaction caused by anti-D. Transfusion 1998, 38:459-468.
81. Wright R.D., Larison P.J., Cook L.O. Plasma exchange in the management of delayed hemolytic transfusion reaction. Transfus Sci 1990, 11:91-96.
82. Win N., Sinha S., Lee E., Mills W. Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review. Transfus Med Rev 2010, 24:64-67.
83. Win N., Yeghen T., Needs M., Chen F.E., Okpala I. Use of intravenous immunoglobulin and intravenous methylprednisolone in hyperhaemolysis syndrome in sickle cell disease. Hematology 2004, 9:433-436.
84. Mota M., Bley C., Aravechia M.G., Hamerschlak N., Sakashita A., Kutner J.M., et al. Autoantibody formation after alloimmunization inducing bystander immune hemolysis. Immunohematology 2009, 25:9-12.
85. Noizat-Pirenne F., Bachir D., Chadebech P., Michel M., Plonquet A., Lecron J.C., et al. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease. Haematologica 2007, 92:e132-e135.
86. Sigler E., Shvidel L., Yahalom V., Berrebi A., Shtalrid M. Clinical significance of serologic markers related to red blood cell autoantibodies production after red blood cell transfusion-severe autoimmune hemolytic anemia occurring after transfusion and alloimmunization: successful treatment with rituximab. Transfusion 2009, 49:1370-1374.
87. Cattoni A., Cazzaniga G., Perseghin P., Zatti G., Gaddi D., Cossio A., et al. An attempt to induce transient immunosuppression pre-erythrocytapheresis in a girl with sickle cell disease, a history of severe delayed hemolytic transfusion reactions and need for hip prosthesis. Hematol Rep 2013, 5:36-38.
88. Stowell S.R., Winkler A.M., Maier C.L., Arthur C.M., Smith N.H., Girard-Pierce K.R., et al. Initiation and regulation of complement during hemolytic transfusion reactions. Clin Dev Immunol 2012, 2012:307093.
89. Wong K.S., Connan K., Rowlands S., Kornman L.H., Savoia H.F. Antenatal immunoglobulin for fetal red blood cell alloimmunization. Cochrane Database Syst Rev 2013, 5:CD008267.